Second-line treatment for metastatic clear cell renal cell cancer: experts’ consensus algorithms-Reference-Cited by-同舟云学术

Second-line treatment for metastatic clear cell renal cell cancer: experts’ consensus algorithms

Published:2016-08-03 Issue:4 Volume:35 Page:641-648
ISSN:0724-4983
Container-title:World Journal of Urology
language:en
Short-container-title:World J Urol

Author:

Rothermundt C.,von Rappard J.,Eisen T.,Escudier B.,Grünwald V.,Larkin J.,McDermott D.,Oldenburg J.,Porta C.,Rini B.,Schmidinger M.,Sternberg C. N.,Putora P. M.

Funder

Pfizer

GlaxoSmithKline Australia

Novartis

AstraZeneca

Bayer

Roche

Bristol-Myers Squibb Canada

AVEO

Astellas Pharma US

Merck

Novartis Pharma

Pierre Fabre

Publisher

Springer Science and Business Media LLC

Subject

Urology

Link

http://link.springer.com/content/pdf/10.1007/s00345-016-1903-6.pdf

Reference24 articles.

1. Escudier B, Porta C, Schmidinger M, Algaba F, Patard JJ, Khoo V, Eisen T, Horwich A, Group EGW (2014) Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(3):49–56. doi: 10.1093/annonc/mdu259

2. Ouzaid I, Rini B (2014) Words of wisdom: re: Pazopanib versus sunitinib in metastatic renal-cell carcinoma. Eur Urol 65(3):667–668. doi: 10.1016/j.eururo.2013.11.023

3. Rothermundt C, Bailey A, Cerbone L, Eisen T, Escudier B, Gillessen S, Grunwald V, Larkin J, McDermott D, Oldenburg J, Porta C, Rini B, Schmidinger M, Sternberg C, Putora PM (2015) Algorithms in the first-line treatment of metastatic clear cell renal cell carcinoma-analysis using diagnostic nodes. Oncologist 20(9):1028–1035. doi: 10.1634/theoncologist.2015-0145

4. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378(9807):1931–1939. doi: 10.1016/s0140-6736(11)61613-9

5. Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, Senico P, Niethammer A, Lu DR, Hariharan S, Motzer RJ (2014) Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 32(8):760–767. doi: 10.1200/JCO.2013.50.3961

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Postoperative radiotherapy for meningiomas – a decision-making analysis;BMC Cancer;2022-05-04

2. First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts;ESMO Open;2021-02

3. Patient Selection for Hyperthermic Intraperitoneal Chemotherapy in Patients With Colorectal Cancer: Consensus on Decision Making Among International Experts;Clinical Colorectal Cancer;2020-12

4. Treatment Options in Oncology;JCO Clinical Cancer Informatics;2018-12

5. Collection of real-world data on nivolumab's effectiveness in renal cell carcinoma: rationale for an observational study;Future Oncology;2018-05